Polaryx Therapeutics develops oral and gene therapy treatments for rare inherited lysosomal storage diseases that mostly affect children. PLYX reports earnings on Thu, Nov 12, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 13 | Raymond James | Initiated | Buy | |
| Jul 27 | LUCID CAPITAL MARKETS | Initiated | Buy | |
| Jul 9 | HC Wainwright & Co. | Initiated | Buy |
Whale Options Flow
90DNo whale options trades in PLYX in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PLYX is in one of them and how their past PLYX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered PLYX in an article yet. Here's the latest on the wider market.
About Polaryx Therapeutics
Polaryx Therapeutics is a biotechnology company based in Paramus, New Jersey, that develops treatments for rare inherited lysosomal storage diseases, which mostly appear in infancy or early childhood. Its most advanced candidate, PLX-200, is an oral medicine being studied in a trial that covers several of these conditions. The company also has other oral candidates in earlier stages and a preclinical gene therapy program. Its intended patients are families affected by these rare diseases, and its treatments are still in development.
- Headquarters
- Paramus, NJ